Notícias e Atividades da Capricor Therapeutics
Executivos
Veja o organograma con seus 17 executivos principais
Biografias mais buscadas da Capricor Therapeutics
- Linda Marban, President, Chief Executive Officer, Director
- Michael Kelliher, Director
- Paul Auwaerter, Director
Recentes movimentos de executivos em Capricor Therapeutics
- Michael Binks, ingressou na Companhia como Chief Medical Officer (Notícia publicada em 20 de maio de 2025).
Criar um alerta
para seguir os movimentos de executivos da Capricor Therapeutics.
Biotecnologia
Capricor Therapeutics possui 2.350 concorrentes concorrentes Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) e Lonza (Suíça).
Popular M&A news in Biotecnologia
- Eli Lilly has announced the acquisition of Verve Therapeutics (publicado em 17 de junho de 2025).
- Sirius Therapeutics acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 16 de junho de 2025).
- BioNTech has announced the acquisition of CureVac (publicado em 12 de junho de 2025).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Capricor Therapeutics
- Capricor Therapeutics to Present at Upcoming Investor Conferences
- Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency
- Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13
- Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
- Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock
- Press Releases
- Capricor Therapeutics Announces Proposed Public Offering of Common Stock
- Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress
- Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
- Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress
- View more press releases Close
Redes sociais sobre Capricor Therapeutics
- Capricor Therapeutics na Wikipedia, Google News e Yahoo Finance
- Capricor Therapeutics na LinkedIn, Twitter e YouTube
